TrialCell reports. Medicine2026

High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial.

Huan Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.